Ranbaxy signs licensing agreement with Debiopharm

39737 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy signs licensing agreement with Debiopharm

Ranbaxy signs licensing agreement with Swiss company Debiopharm, for NCE Drug in the Gastroenterology Segment

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ranbaxy Q3 pat up 651% at Rs 1404 mn Not eyeing any acquisition in France: Ranbaxy Ranbaxy Q3 net profit at Rs 140cr Ranbaxy's revenue growth to be led by Terapia acquisition Ranbaxy Q3 net profit seen at Rs 179cr ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 25/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories Limited (Ranbaxy) today announced that the Company has signed an exclusive licensing agreement with The Debiopharm Group (Debiopharm), a Swiss biopharmaceutical development company, to market its New Chemical Entity (NCE), Sanvar® (vapreotide acetate). The injectable molecule  will be used for the treatment of acute variceal bleeding and prevention of rebleeding related to portal hypertension.   Sanvar can be used in combination with specific treatment such as sclerotherapy or band ligation. Ranbaxy will have exclusive marketing rights in the territories of India, Bangladesh and Nepal.

Sanvar® has been granted orphan drug status in the US where it is presently undergoing Phase III clinical trials. Debiopharm expects to file Sanvar® for approval in the US in Q1 2007.

Commenting on the agreement, Mr. Sanjeev Dani, Regional Director, India & Middle East, Ranbaxy, said, "We are glad to partner with Debiopharm in the Gastroenterology area and shall work towards creating a productive relationship by complementing each others strengths. The agreement will enable Ranbaxy to increase its focus in this segment".

"Debiopharm is pleased to sign agreements with recognized industry leader like Ranbaxy. These partnerships demonstrate the value that Sanvar can add to a growing portfolio of late-stage compounds and we look forward to developing these, and future relationships, to maximize the potential of the product," said Loic Maurel, President and CEO of the Canadian affiliate of Debiopharm.

Contd on page 2...